HTG Molecular Diagnostics, Inc. ("HTG") is a provider of instruments, reagents, and services for molecular profiling applications. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTG’s proprietary nuclease protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power of
HTG EdgeSeq chemistry and automation with next-generation sequencing (NGS) technology. In 2016, the VERI/O Laboratory Services were introduced to support biopharma clients in research and companion diagnostic development using retrospective samples. Most recently, in 2017, HTG introduced its new DNA mutations chemistry available exclusively in the VERI/O Laboratory Services.  

Mission and Values


HTG's mission is to empower precision medicine at the local level. 


  • Embrace the mission
  • Assume Positive Intent
  • Expect Healthy Tension
  • Build Community
  • Engage (I am present and make a difference every day)



Timothy (TJ) B. Johnson
President and Chief Executive Officer

John L. Lubniewski
Chief Business Officer

Shaun D. McMeans
Vice President of Finance, Administration and Chief Financial Officer

Patrick (Pat) C. Roche, Ph.D.
Senior Vice President, Research and Development

Debra (Deb) A. Gordon, Ph.D., J.D.
Vice President, Chief Legal Counsel

Sam M. Rua, Jr.
Vice President of Regulatory Affairs and Quality Systems

Read Bios


Board of Directors

Ann F. Hanham, Ph.D.

Harry A. George

Donnie (Don) M. Hardison

Timothy (TJ) B. Johnson

James (Jim) T. LaFrance

Lee R. McCracken

Lewis (Lew) J. Shuster

Read Bios

Page last updated January 03, 2018